Arcus Biosciences Inc (NYSE: RCUS) Could Be Viewed Differently By Investors Because Of These Numbers

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Recently, Yahoo Finance discussed the stock, revealing that Arcus Biosciences Announces New Employment Inducement Grants.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Stocks Info

The company is listed on the NYSE and operates within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $15.81 and fluctuated between $16.12 as its day high and $15.22 as its day low. The current market capitalization of Arcus Biosciences Inc is $1.18B. A total of 0.87 million shares were traded on the day, compared to an average of 1.13 shares.

Insider Activity

Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, RCUS has seen 0 BUY and 1 SELL insider trades, representing the acquisition of 0 and the disposition of 21,521 shares. Over the last 12 months, there were 8 BUYs and 15 SELLs from insiders. Insiders purchased 1,057,600 shares during that period but sold 215,878.

In the most recent transaction, GILEAD SCIENCES, INC. bought 15,238,095 shares of RCUS for 21.00 per share on Jan 29. After the transaction, the 10% Owner now owns 30,061,124 company shares. In a previous transaction on Jan 02, Jaen Juan C. sold 6,975 shares at 20.09 per share. RCUS shares that President owns now total 1,215,265.

Among the insiders who sold shares, Goeltz II Robert C. disposed of 2,004 shares on Jan 02 at a per-share price of $20.00. This resulted in the Chief Financial Officer holding 51,831 shares of RCUS after the transaction. In another insider transaction, Jarrett Jennifer sold 21,521 shares at $17.76 per share on Dec 22. Company shares held by the Chief Operating Officer now total 258,878.

It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for RCUS in the last 3 months, the mean price target is $39.40 with high estimates of $70.00 and low estimates of $25.00. In terms of 52-week highs and lows, RCUS has a high of $25.47 and a low of $12.95.

As of this writing, RCUS has an earnings estimate of $Arcus Biosciences, Inc. per share for the current quarter. EPS was calculated based on a consensus of Cirrus Logic, Inc. estimates, with a high estimate of $RCS per share and a lower estimate of $Radius Recycling, Inc.

Balance Sheet Annually/Quarterly

An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. RCUS’s latest balance sheet shows that the firm has $499.00M in Cash & Short Term Investments as of fiscal 2021. There were $116.89M in debt and $166.00M in liabilities at the time. Its Book Value Per Share was $6.95, while its Total Shareholder’s Equity was $842.00M.

Analysts Opinion

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RCUS is Buy with a score of 4.80.

Most Popular

Related Posts